A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials

Sun Yat-sen University110 enrolled

Overview

This study focuses on the population of malignant lymphoma patients who are also in clinical research. Through a real world cross-sectional survey of infection and death risk during the COVID-19 pandemic in Guangzhou from December 2022 to January 2023, this study aims to clarify the risk, level and mortality of lymphoma patients infected with COVID-19 during their clinical research, and provide necessary research data for Chinese lymphoma patients during the COVID-19 pandemic,

Study Type

OBSERVATIONAL

Enrollment

110

Conditions

Malignant Lymphoma Clinical Trial COVID-19

Interventions

No interventionOTHER

No intervention needed

Medical Language ↔ Plain English

Inclusion Criteria: (1) the diagnosis of lymphoma was confirmed by pathology according to World Health Organization (WHO)-criteria; (2) diagnosed with COVID-19 based on a positive polymerase chain reaction (PCR) test result for SARS-CoV-2 from oropharyngeal swabs, or on a positive detection of covid-19 antigen from nasopharyngeal swabs and typical clinical history; (3) participated in registered clinical trials and received anti-lymphoma treatment within four weeks before COVID-19 infection; (4) complete data on clinico-pathological characteristics, treatment approaches and follow-up were available. Exclusion Criteria: * Patients who could not provide detailed information about COVID-19 infection.

Outcomes

Primary Outcomes

The severity of COVID-19

The severity of COVID-19 infection in maligant lymphoma patients evaluated by investigators

Time frame: 2 months

Hospital admission rate of COVID-19 infection

The percentage of malignant lymphoma patients who were admitted into hospital